Literature DB >> 15605303

Clinical aspects of fatty liver disease.

Jayanta Choudhury1, Arun J Sanyal.   

Abstract

The global emergence of obesity as an epidemic has made fatty liver disease a public health problem in the Western world. The increased incidence of obesity has been paralleled by an increase in metabolic syndrome in the same cohort of patients. The net consequence of insulin resistance in a large majority of these obese individuals is hepatic steatosis, which over time in a proportion of these patients progresses to steatohepatitis and cirrhosis. Despite the increased awareness among physicians regarding its presence, the diagnostic process has been hampered by the lack of sensitive and specific population-based screening tests. Liver biopsy remains the gold standard for diagnosis as well as for grading and staging of the disease process but its precise role in the diagnostic conundrum continues to be debated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605303     DOI: 10.1055/s-2004-860864

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  22 in total

1.  Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease.

Authors:  Lauren N Bell; Janice L Theodorakis; Raj Vuppalanchi; Romil Saxena; Kerry G Bemis; Mu Wang; Naga Chalasani
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

2.  Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.

Authors:  Samer G Mattar; Laura M Velcu; Mordechai Rabinovitz; A J Demetris; A M Krasinskas; Emma Barinas-Mitchell; George M Eid; Ramesh Ramanathan; Debra S Taylor; Philip R Schauer
Journal:  Ann Surg       Date:  2005-10       Impact factor: 12.969

3.  The relationship between sugar-sweetened beverages and liver enzymes among healthy premenopausal women: a prospective cohort study.

Authors:  Maya K Shimony; Karen C Schliep; Enrique F Schisterman; Katherine A Ahrens; Lindsey A Sjaarda; Yaron Rotman; Neil J Perkins; Anna Z Pollack; Jean Wactawski-Wende; Sunni L Mumford
Journal:  Eur J Nutr       Date:  2015-03-24       Impact factor: 5.614

Review 4.  Non-alcoholic fatty liver disease in 2015.

Authors:  Monjur Ahmed
Journal:  World J Hepatol       Date:  2015-06-18

Review 5.  [Early diagnosis of liver diseases].

Authors:  M M Dollinger; L Fechner; W E Fleig
Journal:  Internist (Berl)       Date:  2005-04       Impact factor: 0.743

6.  Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients.

Authors:  Víctor Vargas; Helena Allende; Albert Lecube; Maria Teresa Salcedo; Juan A Baena-Fustegueras; José M Fort; Joaquín Rivero; Roser Ferrer; Roberto Catalán; Eva Pardina; Santiago Ramón Y Cajal; Jaime Guardia; Julia Peinado-Onsurbe
Journal:  World J Hepatol       Date:  2012-12-27

7.  First-degree relatives of patients with type 2 diabetes mellitus and risk of non-alcoholic Fatty liver disease.

Authors:  Atoosa Adibi; Mohsen Janghorbani; Sanaz Shayganfar; Masoud Amini
Journal:  Rev Diabet Stud       Date:  2008-02-10

8.  Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage.

Authors:  Masato Yoneda; Hironori Mawatari; Koji Fujita; Kyoko Yonemitsu; Shingo Kato; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Yasunobu Abe; Kensuke Kubota; Satoru Saito; Tomoyuki Iwasaki; Yasuo Terauchi; Shinji Togo; Shiro Maeyama; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2007-05-25       Impact factor: 7.527

9.  Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease.

Authors:  Lori D Houghton-Rahrig; Debra L Schutte; Alexander von Eye; Jenifer I Fenton; Barbara A Given; Norman G Hord
Journal:  Nurs Outlook       Date:  2013 Jul-Aug       Impact factor: 3.250

10.  Practice patterns in screening for varices: an American survey.

Authors:  A S Barritt; M R Arguedas
Journal:  Dig Liver Dis       Date:  2009-02-28       Impact factor: 4.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.